by Madaline Spencer | Dec 12, 2024
Steve Hughes, MD, Chief Medical Officer of Avidity Biosciences, discusses the initiation of a biomarker cohort in the Phase 1/2 FORTITUDE trial of delpacibart braxlosiran (del-brax) in patients with facioscapulohumeral muscular dystrophy (FSHD). FSHD is...
by Madaline Spencer | Dec 11, 2024
Courtney Olson, MD, Beth Israel Deaconess Medical Center, discusses results of a survey of patients with hereditary angioedema (HAE) and their preferences for an oral long-term prophylactic (LTP) treatment. HAE is a rare disease characterized by...
by Madaline Spencer | Dec 10, 2024
Bruce Leuchter, MD, CEO of Neurvati Neurosciences and GRIN Therapeutics, discusses the initiation of the Astroscape clinical trial for tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. TSC is characterized by the growth of...
by Madaline Spencer | Dec 9, 2024
Obi Umeh, MD, VP, Franchise Global Program Leader at Takeda, discusses positive interim results from study of mezagitamab for IgA nephropathy. IgA nephropathy is a kidney disorder that occurs when IgA accumulates in the kidneys. In the early stages,...
by Madaline Spencer | Dec 6, 2024
Darcy Trimpe, PhD, U.S. Medical Director at Amgen, discusses real world data on Tavneos (avacopan) for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). GPA is a type of vasculitis of the blood vessels. The disease can...
